A novel AMPK activator reduces glucose uptake and inhibits tumor progression in a mouse xenograft model of colorectal cancer

Silvia Valtorta, Gabriella Nicolini, Farida Tripodi, Cristina Meregalli, Guido Cavaletti, Federica Avezza, Luca Crippa, Gloria Bertoli, Francesca Sanvito, Paola Fusi, Roberto Pagliarin, Fulvia Orsini, Rosa Maria Moresco, Paola Coccetti

Research output: Contribution to journalArticle

8 Citations (Scopus)

Abstract

Summary: The anticancer activity of a novel pure 1,4-Diaryl-2-azetidinone (1), endowed with a higher solubility than the well known Combretastatin A4, is tested in mice. We previously reported that Compound (1) showed specific antiproliferative activity against duodenal and colon cancer cells, inducing activation of AMP-activated protein kinase and apoptosis. Here we estimate that the maximum tolerated dose in a mouse model is 40 mg/kg; the drug is well tolerated both in single dose and in repeated administration schedules. The drug displays a significant antitumor activity and a tumor growth delay when administered at the MTD both in single and fractionated i.v. administration in a mouse xenograft model of colorectal cancer. Arrest of tumor growth and relapse after drug suspension are parallel to modification in glucose demand as shown by PET studies with [18∈F] FDG. These data strongly support Compound (1) as a promising molecule for in vivo treatment of colorectal cancer.

Original languageEnglish
Pages (from-to)1123-1133
Number of pages11
JournalInvestigational New Drugs
Volume32
Issue number6
DOIs
Publication statusPublished - Dec 1 2014

Fingerprint

AMP-Activated Protein Kinases
Heterografts
Colorectal Neoplasms
Glucose
Duodenal Neoplasms
Pharmaceutical Preparations
Neoplasms
Maximum Tolerated Dose
Fluorodeoxyglucose F18
Growth
Solubility
Colonic Neoplasms
Suspensions
Appointments and Schedules
Apoptosis
Recurrence

Keywords

  • Azetidinones
  • Colorectal cancer
  • Combretastatin A4 (CA-4)
  • PET
  • Xenograft

ASJC Scopus subject areas

  • Pharmacology
  • Pharmacology (medical)
  • Oncology
  • Medicine(all)

Cite this

Valtorta, S., Nicolini, G., Tripodi, F., Meregalli, C., Cavaletti, G., Avezza, F., ... Coccetti, P. (2014). A novel AMPK activator reduces glucose uptake and inhibits tumor progression in a mouse xenograft model of colorectal cancer. Investigational New Drugs, 32(6), 1123-1133. https://doi.org/10.1007/s10637-014-0148-8

A novel AMPK activator reduces glucose uptake and inhibits tumor progression in a mouse xenograft model of colorectal cancer. / Valtorta, Silvia; Nicolini, Gabriella; Tripodi, Farida; Meregalli, Cristina; Cavaletti, Guido; Avezza, Federica; Crippa, Luca; Bertoli, Gloria; Sanvito, Francesca; Fusi, Paola; Pagliarin, Roberto; Orsini, Fulvia; Moresco, Rosa Maria; Coccetti, Paola.

In: Investigational New Drugs, Vol. 32, No. 6, 01.12.2014, p. 1123-1133.

Research output: Contribution to journalArticle

Valtorta, S, Nicolini, G, Tripodi, F, Meregalli, C, Cavaletti, G, Avezza, F, Crippa, L, Bertoli, G, Sanvito, F, Fusi, P, Pagliarin, R, Orsini, F, Moresco, RM & Coccetti, P 2014, 'A novel AMPK activator reduces glucose uptake and inhibits tumor progression in a mouse xenograft model of colorectal cancer', Investigational New Drugs, vol. 32, no. 6, pp. 1123-1133. https://doi.org/10.1007/s10637-014-0148-8
Valtorta, Silvia ; Nicolini, Gabriella ; Tripodi, Farida ; Meregalli, Cristina ; Cavaletti, Guido ; Avezza, Federica ; Crippa, Luca ; Bertoli, Gloria ; Sanvito, Francesca ; Fusi, Paola ; Pagliarin, Roberto ; Orsini, Fulvia ; Moresco, Rosa Maria ; Coccetti, Paola. / A novel AMPK activator reduces glucose uptake and inhibits tumor progression in a mouse xenograft model of colorectal cancer. In: Investigational New Drugs. 2014 ; Vol. 32, No. 6. pp. 1123-1133.
@article{15b14cd0ec7b4e16946fccfb35b238da,
title = "A novel AMPK activator reduces glucose uptake and inhibits tumor progression in a mouse xenograft model of colorectal cancer",
abstract = "Summary: The anticancer activity of a novel pure 1,4-Diaryl-2-azetidinone (1), endowed with a higher solubility than the well known Combretastatin A4, is tested in mice. We previously reported that Compound (1) showed specific antiproliferative activity against duodenal and colon cancer cells, inducing activation of AMP-activated protein kinase and apoptosis. Here we estimate that the maximum tolerated dose in a mouse model is 40 mg/kg; the drug is well tolerated both in single dose and in repeated administration schedules. The drug displays a significant antitumor activity and a tumor growth delay when administered at the MTD both in single and fractionated i.v. administration in a mouse xenograft model of colorectal cancer. Arrest of tumor growth and relapse after drug suspension are parallel to modification in glucose demand as shown by PET studies with [18∈F] FDG. These data strongly support Compound (1) as a promising molecule for in vivo treatment of colorectal cancer.",
keywords = "Azetidinones, Colorectal cancer, Combretastatin A4 (CA-4), PET, Xenograft",
author = "Silvia Valtorta and Gabriella Nicolini and Farida Tripodi and Cristina Meregalli and Guido Cavaletti and Federica Avezza and Luca Crippa and Gloria Bertoli and Francesca Sanvito and Paola Fusi and Roberto Pagliarin and Fulvia Orsini and Moresco, {Rosa Maria} and Paola Coccetti",
year = "2014",
month = "12",
day = "1",
doi = "10.1007/s10637-014-0148-8",
language = "English",
volume = "32",
pages = "1123--1133",
journal = "Investigational New Drugs",
issn = "0167-6997",
publisher = "Kluwer Academic Publishers",
number = "6",

}

TY - JOUR

T1 - A novel AMPK activator reduces glucose uptake and inhibits tumor progression in a mouse xenograft model of colorectal cancer

AU - Valtorta, Silvia

AU - Nicolini, Gabriella

AU - Tripodi, Farida

AU - Meregalli, Cristina

AU - Cavaletti, Guido

AU - Avezza, Federica

AU - Crippa, Luca

AU - Bertoli, Gloria

AU - Sanvito, Francesca

AU - Fusi, Paola

AU - Pagliarin, Roberto

AU - Orsini, Fulvia

AU - Moresco, Rosa Maria

AU - Coccetti, Paola

PY - 2014/12/1

Y1 - 2014/12/1

N2 - Summary: The anticancer activity of a novel pure 1,4-Diaryl-2-azetidinone (1), endowed with a higher solubility than the well known Combretastatin A4, is tested in mice. We previously reported that Compound (1) showed specific antiproliferative activity against duodenal and colon cancer cells, inducing activation of AMP-activated protein kinase and apoptosis. Here we estimate that the maximum tolerated dose in a mouse model is 40 mg/kg; the drug is well tolerated both in single dose and in repeated administration schedules. The drug displays a significant antitumor activity and a tumor growth delay when administered at the MTD both in single and fractionated i.v. administration in a mouse xenograft model of colorectal cancer. Arrest of tumor growth and relapse after drug suspension are parallel to modification in glucose demand as shown by PET studies with [18∈F] FDG. These data strongly support Compound (1) as a promising molecule for in vivo treatment of colorectal cancer.

AB - Summary: The anticancer activity of a novel pure 1,4-Diaryl-2-azetidinone (1), endowed with a higher solubility than the well known Combretastatin A4, is tested in mice. We previously reported that Compound (1) showed specific antiproliferative activity against duodenal and colon cancer cells, inducing activation of AMP-activated protein kinase and apoptosis. Here we estimate that the maximum tolerated dose in a mouse model is 40 mg/kg; the drug is well tolerated both in single dose and in repeated administration schedules. The drug displays a significant antitumor activity and a tumor growth delay when administered at the MTD both in single and fractionated i.v. administration in a mouse xenograft model of colorectal cancer. Arrest of tumor growth and relapse after drug suspension are parallel to modification in glucose demand as shown by PET studies with [18∈F] FDG. These data strongly support Compound (1) as a promising molecule for in vivo treatment of colorectal cancer.

KW - Azetidinones

KW - Colorectal cancer

KW - Combretastatin A4 (CA-4)

KW - PET

KW - Xenograft

UR - http://www.scopus.com/inward/record.url?scp=84938688375&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84938688375&partnerID=8YFLogxK

U2 - 10.1007/s10637-014-0148-8

DO - 10.1007/s10637-014-0148-8

M3 - Article

VL - 32

SP - 1123

EP - 1133

JO - Investigational New Drugs

JF - Investigational New Drugs

SN - 0167-6997

IS - 6

ER -